Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure i...
用于哮喘(包括夜间哮喘和运动性哮喘)、喘息性支气管炎和可逆性气道阻塞。
Research Site, Lund, Sweden
GSK Investigational Site, Spokane, Washington, United States
Pfizer Investigational Site, Izmir, Turkey
Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of
Massachusetts General Hospital, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
1184.24.32001 Boehringer Ingelheim Investigational Site, Genk, Belgium
1184.24.32002 Boehringer Ingelheim Investigational Site, Hasselt, Belgium
1184.24.31001 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands
1184.15.37153 Boehringer Ingelheim Investigational Site, Tukums, Latvia
1184.15.01071 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States
1184.15.45054 Boehringer Ingelheim Investigational Site, Aalborg, Denmark
1184.14.01006 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
1184.14.01015 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States
1184.14.31001 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands
Spartanburg Medical Research, Spartanburg, South Carolina, United States
UCLA David Geffen School of Medicine, Los Angeles, California, United States
Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
Novartis Investigative Site, Barcelona, Spain
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.